{"id":"W3146717266","doi":"10.1093/annonc/mdx370.053","title":"The TRITON clinical trial programme: Evaluation of the PARP inhibitor rucaparib in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Enzalutamide; Olaparib; PARP inhibitor; PALB2; Prostate cancer; Oncology; Taxane; Internal medicine; CHEK2; Docetaxel; Cancer research; Germline mutation; Cancer; Androgen receptor; Breast cancer; Mutation; Genetics; Poly ADP ribose polymerase; Biology; Gene","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001371722,0.00169975,0.002074908,0.0005400005,0.0004481002,0.001669087,0.0009949555,0.001698411,0.007876706],"category_scores_gemma":[0.001686588,0.0005736185,0.001695785,0.0006498001,0.001118934,0.001207677,0.0005903513,0.004395985,0.001657242],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007559076,"about_ca_system_score_gemma":0.001548063,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001380576,"about_ca_topic_score_gemma":0.003025632,"domain_scores_codex":[0.9995523,0.0002496199,0.0000228358,0.00006420848,0.0000388679,0.00007206159],"domain_scores_gemma":[0.9992802,0.0001373622,0.000179554,0.00006605328,0.00004976486,0.0002871384],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9197453,0.01329086,0.003027312,0.000767254,0.001230435,0.000187728,0.0001518841,0.001534679,0.006793641,0.0006028251,0.005264301,0.04740374],"study_design_scores_gemma":[0.823765,0.1646419,0.005825571,0.00006187242,0.0005242524,0.0002015052,0.00007599827,0.0006045475,0.0006797441,0.0002563854,0.003330942,0.00003222757],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9762013,0.003533588,0.0007957016,0.00200305,0.0004040748,0.004398867,0.004557349,0.0002125073,0.0078936],"genre_scores_gemma":[0.969713,0.004795723,0.001891681,0.001806056,0.0004661058,0.005142291,0.006764772,0.00008437562,0.009335969],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007876706,"threshold_uncertainty_score":0.02635014,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2420030461297958,"score_gpt":0.4813160704545564,"score_spread":0.2393130243247606,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}